Physician profile
David Jude Magee
NPI 1861452955
$7,862.72
in general payments reported to CMS, 2019-2025
36 companies · $1,641 in 2025
The $1,641 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $500 · 2020: $589 · 2021: $1,015 · 2022: $1,491 · 2023: $1,290 · 2024: $1,335 · 2025: $1,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,252 · Education: $14.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,252.17 |
| Education | $14.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,066.84 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $826.59 | 2020-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $613.69 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Genzyme Corporation | $332.91 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $279.49 | 2022-2024 | Dificid, Zerbaxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.52 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $176.83 | 2022-2025 | Dupixent |
| Pfizer INC. | $165.71 | 2023-2025 | |
| Qol Medical, LLC | $130.89 | 2021-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $112.74 | 2022-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $98.44 | 2023-2025 | Voquezna |
| Amgen INC. | $76.79 | 2022-2023 | Amjevita, Avsola |
| Shield Therapeutics INC | $73.91 | 2024 | |
| Celgene Corporation | $62.44 | 2022-2024 | Zeposia |
| Redhill Biopharma INC. | $56.44 | 2020-2023 | Movantik, Talicia, Aemcolo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $52.93 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $52.23 | 2019-2023 | Linzess |
| Ipsen Biopharmaceuticals, INC | $51.47 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $49.32 | 2025 | Ibsrela |
| Vivus LLC | $35.37 | 2022-2024 | Qsymia |
| Tersera Therapeutics LLC | $35.15 | 2023 | Quzyttir |
| Celltrion USA INC. | $33.78 | 2023-2025 | Vegzelma, Yuflyma |
| Micro-Tech Endoscopy USA, INC. | $32.96 | 2021-2024 | Riteclip |
| Ferring Pharmaceuticals INC. | $31.39 | 2020-2022 | |
| Mauna Kea Technologies, INC. | $27.63 | 2024 | |
| Phadia US INC. | $27.55 | 2024 | Immunocap |
| Lilly USA, LLC | $25.83 | 2024 | Omvoh |
| Novo Nordisk INC | $20.26 | 2025 | Wegovy |
| Gilead Sciences, INC. | $19.97 | 2019 | |
| Mylan Institutional INC. | $19.15 | 2023 | |
| Daiichi Sankyo INC. | $18.98 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.04 | 2021 | |
| Enterra Medical, INC. | $14.64 | 2023 | |
| Allergan, INC. | $14.44 | 2019 | |
| Capsovision, INC. | $13.40 | 2024 | Capsocam Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,338.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.